Sphingolipid serum profiling in vitamin D deficient and dyslipidemic obese dimorphic adults by N.M. Al-Daghri et al.
1Scientific RepoRtS |         (2019) 9:16664  | https://doi.org/10.1038/s41598-019-53122-4
www.nature.com/scientificreports
Sphingolipid serum profiling 
in vitamin D deficient and 
dyslipidemic obese dimorphic 
adults
nasser M. Al-Daghri1, Enrica torretta2,7, pietro Barbacini2,7, Hannah Asare3, cristian Ricci  3, 
Daniele capitanio2,4, Franca Rosa Guerini5, Shaun B. Sabico1, Majed S. Alokail1, Mario Clerici5,6 
& Cecilia Gelfi  2,4*
Recent studies on Saudi Arabians indicate a prevalence of dyslipidemia and vitamin D deficiency 
(25(OH)D) in both normal weight and obese subjects. In the present study the sphingolipid pattern 
was investigated in 23 normolipidemic normal weight (NW), 46 vitamin D deficient dyslipidemic 
normal weight (-vitDNW) and 60 vitamin D deficient dyslipidemic obese (-vitDO) men and women 
by HPTLC-primuline profiling and LC-MS analyses. Results indicate higher levels of total ceramide 
(Cer) and dihydroceramide (dhCers C18–22) and lower levels of total sphingomyelins (SMs) and 
dihydrosphingomyelin (dhSM) not only in -vitDO subjects compared to NW, but also in –vitDNW 
individuals. A dependency on body mass index (BMI) was observed analyzing specific Cer acyl 
chains levels. Lower levels of C20 and 24 were observed in men and C24.2 in women, respectively. 
Furthermore, LC-MS analyses display dimorphic changes in NW, -vitDNW and –vitDO subjects. In 
conclusion, LC-MS data identify the independency of the axis high Cers, dhCers and SMs from obesity 
per se. Furthermore, it indicates that long chains Cers levels are specific target of weight gain and that 
circulating Cer and SM levels are linked to sexual dimorphism status and can contribute to predict obese 
related co-morbidities in men and women.
Obesity is a globally expanding pathology and up to 58% of the world’s adult population is expected to be over-
weight or obese by 20301. This condition is associated with vitamin D deficiency and is more common in women 
(11% of men and 15% of women were obese in 2014)2–4. Although a causal genetic association between obe-
sity and vitamin D (25(OH) D) deficiency has been described5, the reasons for this association have not yet 
been clarified and could include a number of factors, such as differences in dietary intake or sun exposure, a 
decreased vitamin D bioavailability or altered vitamin D metabolism6. Furthermore, low plasma levels of vitamin 
D have been associated with obesity-related health complications, such as insulin resistance, type 2 diabetes and 
dyslipidemia7–9.
A recent differential proteomic study of sera of obese men and women from Saudi Arabia, in whom low 
vitamin D concentrations were present, identified a number of proteins that are differentially expressed in obese 
compared to lean weight people; these proteins belong to different pathways, including lipid metabolism, vita-
min D function and immunity/inflammation10. Serum profiling by MALDI mass spectrometry on these same 
individuals indicated that increased inflammation and altered lipid metabolism were present in obese subjects11. 
Furthermore, polymorphisms of the synaptosomal-associated protein 25 (SNAP-25) gene associated with insulin 
resistance have been identified in obese individuals; in particular, the SNAP25 rs363050 (G) allele was shown to 
result in a reduced expression of SNAP25, associated with altered glycemic parameters12.
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Recently, increased attention has been focused on circulating levels of ceramide (Cer) and ceramide deriv-
atives associated with obesity and liver steatosis, highlighting the relationship between obesity and circulating 
lipids13–16.
Thus, obese insulin-resistant individuals are characterized by significantly increased plasma Cer concentra-
tion, compared to lean, insulin sensitive subjects14. The dependence of Cer synthesis on saturated fats can provide 
a direct link between sphingolipids, dyslipidemia and insulin signaling17,18. Furthermore, it has been described 
that sphingolipid (SL) concentration, in association with adiponectin, IL-6 and insulin resistance, contributes to 
sexual dimorphism of the adipose tissue distribution in humans19.
Recent data indicate that plasma Cer is mainly concentrated in VLDL and LDL particles, that LDL-bound Cer 
promote inflammation and insulin resistance in skeletal muscle20, and that Cer levels correlate with LDL levels 
and cardiovascular risk21. To make the picture more complex, quali /quantitative results of SLs are characterized 
by high variability due to their peculiar chemico-physical properties and their wide serum dynamic range. In 
serum, sphingomyelins (SM) account for 87% of all SLs, and Cer account for 2.8%22. Recently, thanks to the 
development of a sphingosine-1-phosphate (S1P)-specific monoclonal antibody23, quantitative measurements 
of S1P plasma levels could be obtained in high fat diet, ob/ob mice and obese patients; results indicated a direct 
association between S1P levels and obesity13.
Nevertheless, an assessment of levels of SLs related to vitamin D deficiency and dyslipidemia and their rela-
tionship with obesity is lacking; these data are needed to shed light on the correlations between these factors. 
Previously, Cer levels were determined considering obese dyslipidemic compared to normal weight normolipi-
demic without considering dyslipidemic normal weight subjects14,24.
This study, based on the combination of a single phase extraction method with a HPTLC-primuline-profiling 
and LC-MS analyses was designed with the goal of analyzing SLs changes in dyslipidemia and vitamin D defi-
ciency, to get better insight into the contribution of SLs in obesity. To this end, we investigated SLs levels in three 
groups of Saudi Arabians: normolipidemic normal weight (NW), vitamin D deficient dyslipidemic normal weight 
(-vitDNW) and vitamin D deficient dyslipidemic obese (-vitDO) subjects. Each group was composed by men 
and women, making possible to assess gender differences in the three groups. Comparison between vitamin D 
deficient lean and obese subjects allowed for analyzing SLs patterns in obesity independently from dyslipidemia, 
thus verifying whether these patterns are linked to weight gain and/or to chronic inflammation.
Results
Subjects’ general characteristics and clinical parameters assessment. Serum samples were col-
lected from 23 normolipidemic normal weight (NW) controls (M/F-15/8), 46 vitamin D deficient dyslipidemic 
(HDL < 1 mmol/L; TG > 2.3 mmol/L) normal weight (-vitDNW) subjects (M/F-23/23) and from 60 vitamin D 
deficient dyslipidemic obese (-vitDO) subjects (M/F-25/35). Epidemiologic data and median serum levels of total 
cholesterol (CHL), glucose (GLU), high density lipoprotein-CHOL (HDL), triglycerides (TRG) and 25(OH)D of 
enrolled Saudi individuals are summarized in Table 1. Gender and age composition were homogeneous across 
groups composed of normal weight and obese subjects (U-test p-value = 0.64, χ2 p-value = 0.15 for age and gen-
der respectively). -vitDNW subjects were characterized by dyslipidemia, with lower levels of HDL and higher 
levels of TRG and total cholesterol compared to NW (U-test p-value < 0.001 for HDL, TRG and total cholesterol), 
and with higher levels of TRG and lower levels of HDL compared to -vitDO (U-test p-value = 0.019 and 0.006 for 
HDL and TRG respectively).
Men Women
Normolipidemic 
normal weight (NW)
Dyslipidemic 
normal weight 
(-vitDNW) Obese (-vitDO)
Normolipidemic 
normal weight (NW)
Dyslipidemic 
normal weight 
(-vitDNW) Obese (-vitDO)
N (%) 15 (11.6%) 23 (17.8%) 25 (19.4%) 8 (6.2%) 23 (17.8%) 35 (27.1%)
Age (year) 39 (35, 44) 47.0 (32.0, 59.0) 44.0 (31.0, 56.0) 39 (26, 48.5) 45.0 (35.0, 55.0) 45.0 (40.0, 56.0)
BMI (kg/m2) 23.3 (22.0, 23.9) 23.4 (22.2, 24.6) 36.7 (34.7, 39.1) 20.7 (19.4, 22.9) 25.6 (24.0, 26.0) 39.9 (37.6, 42.6)
WC (cm) — 88.9 (81.0, 93.0) 117 (113, 123) — 91 (82, 102) 105 (98.2, 112)
BP (cm) — 86.0 (39.0, 98.0) 116 (53, 126) — 103 (94, 106) 121 (115, 129)
SBP (mmHg) — 122 (113, 130) 130 (120, 141) — 125 (110, 130) 130 (117, 132)
DBP (mmHg) — 71.5 (68.0, 76.0) 80.0 (68.5, 90.0) — 80.0 (70.0, 82.0) 80.0 (72.0, 83.0)
GLU (mmol/l) — 6.3 (5.0, 9.9) 7.0 (5.9, 14.4) — 6.2 (4.7, 11.8) 8.0 (6.0, 11.6)
CHL (mmol/l) 4.6 (4.3, 4.8) 4.9 (4.4, 6.1) 5.4 (4.7, 6.0) 4.4 (4.0, 4.6) 5.4 (4.7, 6.2) 5.4 (4.7, 6.0)
HDL (mmol/l) 1.76 (1.71, 1.86) 0.7 (0.6, 0.8) 0.8 (0.6, 0.8) 1.47 (1.45, 1.63) 0.7 (0.6, 0.8) 0.8 (0.7, 0.9)
TRG (mmol/l) 0.90 (0.7, 1.50) 3.4 (3.0, 4.2) 3.2 (2.9, 3.9) 0.78 (0.65, 0.91) 3.4 (2.8, 4.1) 3.0 (2.7, 3.3)
25(OH) D (nmol/l) 75.4 (65.7, 88.9) 32.7 (21.9, 40.8) 34.0 (26.6, 37.6) 78.9(65.2, 84.2 22.0 (14.4, 37.0) 31.0 (21.5, 42.0)
Table 1. Characteristics of participants. Continuous variables were described by median and interquartile 
range, categorical variables were reported as counts and percentages. Notes: BMI Body Mass Index, WC Waist 
Circumference, BP Buttocks Perimeter, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, GLU 
Glucose, CHL Cholesterol, HDL High Density lipo-protein, TRG triglycerides.
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Variations in ceramide and sphingomyelin profiles. To identify variations in total ceramide (Cer) and 
total sphingomyelin (SM) levels associated to dyslipidemia, vitamin D deficiency and obesity, HPTLC-primuline 
profiling was performed on SLs extracted from NW (n = 15), -vitDNW (n = 23) and -vitDO (n = 25) men and 
from NW (n = 8), -vitDNW (n = 23) and -vitDO (n = 35) women. After separation on HPTLC plates, SL bands 
were compared by a profiling approach based on HPTLC-densitometry and FDIC (fluorescence detection by 
intensity changes) emission after primuline staining (data shown in Fig. S1).
From primuline stained HPTLC plates, bands corresponding to Cer and SM were identified by Rf comparison 
with standards, carrying a variation coefficient (CV) of 6–7%; bands with Rf = 0.923, Rf = 0.858, Rf = 0.176 and 
Rf = 0.152 respectively, were attributed to Cers (C20-C24), Cers (C14-C18), SMs (C20-C24) and SMs (C14-C18) 
(Fig. S2).
Primuline quantitative staining revealed a statistically significant increase in Cers (C14-C18) levels 
in -vitDNW and -vitDO compared to NW control subjects (omnibus p-value < 0.001, NW vs -vitDO 
p-value < 0.001, NW vs -vitDNW p-value < 0.001) (Fig. 1A). To get better insight into the acyl chain qualitative 
and quantitative composition of the sphingolipidome, LC-MS analyses were conducted on 4 sub-pools per group, 
both for men and women (24 total sub-pools). Total Cer levels were higher in –vitDNW and in –vitDO compared 
to NW (p-value < 0.01) (Fig. 1B), as the Cers C16:0, C20:0, C22:0, C22:1, C24:0, C24:1, C24:2, whereas Cers 
C20:0 and C24:1 were lower in –vitDO men compared to –vitDNW men, while only C24:2 was lower in –vitDO 
women compared to -vitDNW women (Fig. S3,A,B). Notably, total dihydroceramide (dhCer) levels were higher 
in –vitDNW compared to NW (p-value < 0.05) (Fig. 1B) and dhCers C18:0, C20:0 and C22:0 acyl chain levels 
were higher both in –vitDNW and in –vitDO compared to NW (Fig. S3,C,D).
Concerning SM levels, NW control subjects showed higher levels of SMs (C14-C18) compared to -vitDNW 
and -vitDO (p < 0.001) (Fig. 1C). Total SMs, together with total dihydrosphingomyelin (dhSMs) (Fig. 1D), were 
lower in –vitDNW and in –vitDO compared to NW, with the same trend of HPTLC-primuline profiling. SM 
specific chains C16:0, C16:1, C18:0, C18:1, C20:1 and C22:1 and dhSM C14:0 and C16:0 were lower compared to 
NW (Fig. S3 E,F). Data from Cers (C20-C24) and SMs (C20-C24) are reported in Fig. 4S.
Sex-related variations in sphingolipid profiles. Gender-specific differences emerged when Cer and SM 
profiles in men and women were compared (Fig. 3S). To get better insight into sex-related variations, the sphingo-
lipid patterns in men and women were directly compared in NW, -vitDNW and –vitDO. NW men compared to 
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Figure 1. (A) Ceramides (Cers) (C14-C18) in sera from normolipidemic normal weight (NW) (n = 15), 
vitamin D deficient dyslipidemic normal weight (-vitDNW) (n = 46) and vitamin D deficient dyslipidemic 
obese (-vitDO) (n = 60) subjects by primuline /HPTLC densitometry. (B) Total Cer and dhCer in sub-pooled 
sera from NW vs –vitDNW vs –vitDO subjects by LC-MS analysis. (C) Sphingomyelins (SMs) (C14-C18) 
in sera from NW, -vitDNW and –vitDO subjects by primuline /HPTLC densitometry. (D) Total SM and 
dhSM in sub-pooled sera from NW vs –vitDNW vs –vitDO subjects by LC-MS analysis. Statistical analysis 
was performed by ANOVA test, with Tukey post-hoc test. Data are expressed in log scale and reported as 
mean ± SD.
4Scientific RepoRtS |         (2019) 9:16664  | https://doi.org/10.1038/s41598-019-53122-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
women were characterized by higher levels of Cers (specifically C20:0, C24:1, C24:2 chains) and of SMs (specifi-
callyC18:0, C20:0, C22:1 and C24:1 chains) (Fig. 2A,B). At variance, –vitDNW women compared to men showed 
higher levels of SM C22:0 (p-value < 0.05) (Fig. 2C). Concerning dhSM and SM in –vitDO men compared to 
women, dhSM C18:0 was higher in men (p-value < 0.05) (Fig. 2D), whereas SM C14:1 was higher in women 
(Fig. 2E).
To investigate levels of sphingosine-1-phospahte (S1P), a sphingolipid recently associated with obesity and 
hypoxia induced obesity13,25, sphingosine, S1P, dihydrosphingosine-1-phosphate (dhS1P), and glycosphingolipids 
as hexosylceramide (HexCer) and dihexosylceramide (diHexCer) (Fig. S5) were analyzed by LC-MS/MS. S1P 
levels were non statistically significant in –vitDNW and –vitDO compared to NW, both for men and women 
(Fig. 3A,B). Concerning dhS1P, in women it was significantly higher in –vitDNW and in –vitDO compared to 
NW (p-value < 0.05) (Fig. 3B).
DiHexCer C18:0 levels were lower in NW men compared to women (p-value < 0.05) (Fig. 4A). In –vitDO 
subjects, higher levels of total HexCer and HexCer C16:0 were observed in women (Fig. 4B). Data from other 
sphingolipid classes in men and women are shown in Fig. S6.
In men, results showed that total diHexCer was lower in –vitDNW and –vitDO compared to NW 
(p-value < 0.05 and <0.01, respectively) (Fig. 4C), whereas in women, total HexCer was higher in –vitDO com-
pared to –vitDNW (p-value <0.01) (Fig. 4D). Concerning levels of specific chains in women: HexCer C16:0 was 
higher in NW and in –vitDO compared to –vitDNW (p-value < 0.05) (Fig. 4E) whereas DiHexCer C24:1 was 
lower in –vitDO and in –vitDNW compared to NW (p-value < 0.01) (Fig. 4F).
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Figure 2. Cer and SM sex-related variations in sub-pooled sera of NW (A,B), -vitDNW (C), and -vitDO 
(D,E) men and women. Statistical analysis was performed by Student t-test. Data are expressed in log scale and 
reported as mean ± SD.
5Scientific RepoRtS |         (2019) 9:16664  | https://doi.org/10.1038/s41598-019-53122-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
We investigated SL levels in three groups of Saudi individuals, normolipidemic with normal weight (NW), com-
pared to vitamin D deficient and dyslipidemic subjects who were either obese (-vitDO) or had normal BMI 
(-vitDNW). Results herein show the presence of a general increase of total Cer in dyslipidemic (both –vitDNW 
and -vitDO) compared to normolipidemic NW subjects, linking total Cer abundance to dyslipidemia and vitamin 
D deficiency. Our results confirmed data showing higher levels of total Cer in obese (-vitDO) subjects compared 
to normolipidemic normal weight (NW) controls20,26,27. More interestingly, data herein for the first time high-
lighted that levels of total Cer are significantly higher not only in obese but also in dyslipidemic normal weight 
subjects. These results suggest that total Cer increase is associated with 25(OH)D deficiency and hyperlipidemia 
independently from obesity per se.
In countertrend with total Cer, total SM and total dhSM, were lower both in –vitDNW and in –vitDO com-
pared to NW, suggesting also in this case a direct correlation of this class of molecules with vitamin D deficiency 
and hyperlipemia.
The strength of the present work is the investigation of sera from obese compared to dyslipemic NW and 
normolipidemic NW subjects that allows a better understanding of the significance of the fine regulation of Cers 
and SMs. In previous studies, sphingolipids abundance was compared in obese and lean healthy subjects13,14,28 
or lean normoglycemic29 controls, without taking into account dyslipidemia. A recent study indicates the same 
relationship among 25(OH)D deficiency, total Cer increase and dyslipidemia in Andean children characterized 
by different BMIs25. It could be speculated that in Saudi Arabian subjects, total Cer increment in -vitDNW and 
–vitDO is related to palmitoyl-CoA /serine and fatty acids de novo biosynthetic route as suggested by the incre-
ment of total dhCer and of dhCer specific chains (Fig. S5)30,31. Ceramide generation, during HFD-induced obe-
sity, is stimulated by the continuous and excessive supply of FFA from diet and adipose tissue providing substrate 
for serine palmitoyl transferase and Ceramide synthase CerS(1–6) isoforms16,32 increasing plasmatic Cer levels. 
Notably, total SM and dhSM were decreased in –vitDNW and in –vitDO, suggesting a higher activity of sphingo-
myelinase in membranes33. In animal models, HFD administration stimulates the expression and the activity of 
both acidic sphingomyelinase (aSMase) and neutral sphingomyelinase (nSMAse)34,35. It has been observed that 
the pharmacological inhibition of aSMase by amitriptyline reduced HFD-stimulated ceramide release in blood36.
Little is known regarding SLs behavior during dyslipidemia and vitamin D deficiency. Thanks to their hydro-
philicity, sphingolipids circulate in plasma bound to albumin and lipoproteins37. Particularly, Cer is present and 
equally distributed in HDL-C, LDL-C and VLDL-C22, while 70% of SM is carried by LDL/VLDL-C and 30% by 
HDL-C22. Interestingly, -vitDNW subjects showed higher levels of total Cer, dhCer and lower levels of total SM 
and dhSM, compared to normolipidemic NW, suggesting that -vitDNW subjects, independently from obesity, 
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Figure 3. LC-MS profile of sphingosine, sphingosine-1-phosphate (S1P) and dihydrosphingosine-1-phosphate 
(dhS1P) in sub-pooled sera from NW, –vitDNW and –vitDO men (A) and women (B). Statistical analysis 
was performed by ANOVA test, with Tukey post-hoc test. Data are expressed in log scale and reported as 
mean ± SD.
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develop a sphingolipid plasma profile that is influenced by LDL-C, HDL-C and TRG levels. It can be speculated 
that normal-weight subjects, with vitamin D deficiency and dyslipidemia, develop altered plasma SL profiles 
because of the differential “transport” capacity of lipoprotein, whereas the alterations observed in obesity are 
related to changes in SLs biosynthesis (e.g., de-novo biosynthesis and sphingomyelinase pathway) (Fig. S5)21.
Specific acyl chains of Cer and SM rather than total levels were found at variance in obesity supporting the role 
of different Cer synthase isoforms in the regulation of SLs production in obesity. Specifically in obese men, we 
found chains of Cer, namely Cers C20:0 and C24:2 at lower levels and higher levels of dhSM C18:0. Obese women 
had lower levels of Cer C24:1 and higher levels of SM C16:0. These results pinpoint the relevance of different Cers 
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Figure 4. Glycosphingolipid sex-related variations in sub-pooled sera of NW (A) and obese (B) men and 
women. LC-MS profiles of total hexosylceramide (HexCer) and dihexosylceramide (diHexCer) in sub-pooled 
sera of NW, -vitDNW, and -vitDO men (C) and women (D) are shown, together with LC-MS levels of C16:0 
HexCer (C) and C24:1 diHexCer (D), resulted to be changed in women. Statistical analysis was performed by 
Student t-test for (A,B) and by ANOVA test, with Tukey post-hoc test for (C–F). Data are expressed in log scale 
and reported as mean ± SD.
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synthase (1–6) isoforms in the regulation of single acyl chain Cer synthesis in obesity. Our results indicate that 
differentially abundant acyl-chains Cer are directly associated with increased SM and dhSM specific chains in 
obese subjects (SM C16:0 in women and dhSM C18:0 in men).
Although sexual dimorphism in body composition is evident in adulthood38, sex has been only sporadically 
considered in metabolomic and lipidomic studies in obesity39. Despite increased levels of circulating free fatty 
acids, women readily oxidize non-esterified plasma fatty acids, increasing ketone bodies production40 or lipid 
re-esterification41 and display improved insulin sensitivity.
Results from the present study indicate in men increased levels of Cer C20:0, C24:1 and C24:2 as a char-
acteristic trait of normolipidemic normal-weight subjects confirming results from a larger cohort of Mexican 
Americans42, that attribute to cerS-2 higher levels of long-chain ceramides.
Also SMs characterized dimorphic changes being SM C18:0, C20:0, C22:1 and C24:1 higher in normolipi-
demic normal-weight men compared to women. These results are in contrast with other studies43–45 that found 
higher levels of SM in women. However, once again, considering dyslipidemic normal-weight and obese women, 
SM were more abundant44, and particularly SM C22:0 and C14:1 were higher compared to men both dyslipidemic 
normal-weight and obese.
Concerning dhS1P, this molecule is present at higher levels in –vitDNW and –vitDO women compared to 
NW. It can be hypothesized that this molecule contributes to keep under control levels of dhCer thus subtracting 
dhCer to total Cer synthesis being levels of total Cer in -vitDNW and -vitDO similarly increased both in men 
and women.
It can be hypothesized that higher levels of hexosylceramide found in obese women could be related to over-
expression of hexosylceramide synthase in adipocytes that suppresses insulin signaling46. Hexosylceramide has 
been described as a possible inducer of plaque inflammation and instability47. It must be stated that due to the 
similarity in the hydrophobic moiety and mass identity, hexosylceramides (glucosylceramides and galactosylcer-
amides) are not easy to separate and quantify by reverse-phase chromatography48, therefore observed changes 
are related to both glucosylceramides and galactosylceramides and further studies will be required to precisely 
identify the contribution of single species to the total pool and the role of different glycosphingolipids.
Although the use of two approaches to study SLs in serum, the quantitative structure-specific measurements 
of all molecular species remains challenging.
The novelty of this study is that it demonstrated for the first time that Cer and SM levels correlate directly with 
dyslipidemia and vitD deficiency independently from BMI and that only specific acyl chains of Cer and SM are 
directly correlated with obesity per se. Furthermore, it highlights the importance of sexual dimorphism in deter-
mining circulating SLs levels independently from serum lipids and vitamin D status. Notably, results obtained in 
normal weight subjects indicated that sex influences serum concentrations of Cer and SM42. We confirmed those 
results and expanded them in the setting of obesity and vitamin D deficiency.
However, the inter-individual variability, the number of samples, the paucity of reference data could be seen 
as limiting factors in this study. These limitations notwithstanding, it is important to underline that results herein 
suggest that these putative biomarkers could be used to predict the risk for vitamin D deficient adult subjects to 
develop associated co-morbidity in obesity.
The possible effect of vitamin D and statins supplementation on Cer levels is currently being investigated in 
our cohorts to better clarify the role of drugs on SLs concentration.
Materials and Methods
Participants and sample collection. Adult male and female Saudis were enrolled from the Vitamin D 
School Project Database of the Prince Mutaib Chair for Biomarkers of Osteoporosis (PMCO), College of Science, 
King Saud University (KSU), Riyadh, Kingdom of Saudi Arabia (KSA)49. All subjects were grouped according to 
Body Mass Index (BMI) into normal weight (BMI < 25 kg/m2) and obese (BMI ≥ 30 kg/m2). The present study 
conforms to the principles of Helsinki Declaration, and was approved by the Ethics Committee of the College of 
Science, KSU, Riyadh, KSA (Ref No.15/0502/IRB). All enrolled subjects provided their full informed consent. 
Serum samples were collected from 23 normolipidemic normal weight (NW) controls, 46 vitamin D deficient 
dyslipidemic (HDL < 1 mmol/L; TG > 2.3 mmol/L) normal weight (-vitDNW) and from 60 vitamin D deficient 
obese (-vitDO) subjects, and stored at −80 °C until use. The general characteristics of enrolled subjects are sum-
marized in Table 1. Vitamin D deficiency was defined as circulating serum 25(OH)D < 50 nmol/l (<20 ng/ml)50.
Reagents and Chemicals. Propan-2-one, methanol, 1-butanol, LC-MS grade water, primuline yellow dye, 
ammonium dihydrogen phosphate, 3,5-Di-tert-4-butylhydroxytoluene (BHT) and ammonium formate were from 
Sigma-Aldrich (Saint Louis, MO, USA). Ethanol and high performance liquid chromatography (HPLC)-analytical 
grade chloroform (CHCl3) were respectively from J.T. Baker (Center Valley, PA, USA) and Carlo Erba (Cornaredo, 
MI, Italy). N-lignoceroyl-D-erythro-sphingosine (Cer C24:0) 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), 
Cardiolipin (CL), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), D-glucosyl-ß-1,1′-N-stearoyl-D
-erythro-sphingosine-d5 (HexCer), N-lauroyl-D-erythro-sphingosine, N-lauroyl-D-erythro-sphinganine, 
N-lauroyl-D-erythro-sphingosylphosphorylcholine N-lauroyl-D-erythro-sphinganylphosphorylcholine, 
D-glucosyl-ß−1,1′-N-lauroyl-D-erythro-sphingosine, D-lactosyl-ß-1,1′ N-lauroyl-D-erythro-sphingosine and C17 
d-erythro-dihydrosphingosine-1-phosphate lipids standards were from Avanti Polar Lipids (Alabaster, Alabama, USA). 
SL standard mixture, containing SM and Sulfatides (SLF) was from Matreya LLC (Pleasant Gap, PA, USA).
Lipid extraction. Sera samples were extracted according to the procedure of Alshehry et al.51, with minor 
modifications, as already described in52.
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Sphingolipid analysis. For sphingolipid analysis two different strategies were considered: High perfor-
mance thin layer chromatography (HPTLC)-primuline profiling were first conducted to analyze all serum sam-
ples (from 23 NW, 46 –vitDNW and –vitDO subjects), whereas LC-MS analysis were carried out on 4 sub-pools 
per group, both for men and women (24 total sub-pools).
The use of primuline as a fluorophore for quantitative purposes was first described by Domínguez et al.53 
as FDIC, i.e. fluorescence detection by intensity changes. FDIC detects fluorescent emission produced by 
non-specific and electrostatic interactions between the primuline and hydrocarbon chains in the ceramide back-
bones of sphingolipids54–57. In our work, primuline was used for semi-quantitative purposes, to detect changes in 
ceramides and sphingomyelins levels among NW, –vitDNW and –vitDO men and women.
HPTLC-Primuline profiling. HPTLC-Primuline profiling analyses were performed according to Torretta 
E. et al.52. For each sample, 100 µg of total protein were loaded in duplicate using Linomat 5 semiautomatic TLC 
spotter (CAMAG, Switzerland).
HPTLC plates were then developed in chloroform/methanol/water 55:20:3 (v/v/v), using Camag Automatic 
Developing Chamber 2 (CAMAG, Switzerland) Developed plates were sprayed with a solution of primuline yel-
low dye, 5 mg/100 ml in propan-2-one/water 80:20 (v/v) and dried under a fume hood. Images from stained 
plates were acquired using Ettan DIGE Imager (GE Healthcare, Chicago, IL, USA). Bands corresponding to Cers 
(C20-C24), Cers (C14-C18), SMs (C20-C24) and SMs (C14-C18) were compared among NW, -vitDNW and –
vitDO, considering primuline as a FDIC (fluorescence detection by intensity changes) fluorophore53,58.
Sphingolipids by LC-MS. For LC-MS analysis, sera were randomly sub-pooled into 4 groups of men and 4 
groups of women, homogeneous for biometric parameters and HPTLC quantitative profiles. SL extracts were ana-
lyzed in the presence of internal standard52, prepared as described by Merrill et al.59, including an alkaline hydrol-
ysis step to remove phospholipids, and analyzed by Waters Aquity Ultra Performance Liquid Chromatography 
(UPLC) system connected to a Waters LCT Premier orthogonal accelerated time of flight mass spectrometer 
(Waters, Millford, MA), operating in positive electrospray ionization mode. Spectra were acquired according 
to52. Positive identification of compounds was based on the accurate mass measurement with an error <5 ppm 
and its LC retention time, compared to that of a standard (±2%). Mass spectra were analyzed by MassLynx™ 4.1 
Software.
LC-MS/MS analyses of sphingosine, S1P and dhS1P were carried out on an Acquity UPLC system coupled 
with a Xevo TQ-MS triple quadrupole mass spectrometer. The mass spectrometer was operated in the positive 
ESI mode, and analytes were quantified by multiple reaction monitoring (MRM). Transitions considered were Q1 
300.4- > Q3 264.4 for Sph, Q1 380.4 - > Q3 264.4 for S1P and Q1 382.4- > Q3 284.4 for dhS1P.
Statistical analysis. Participants were grouped according to sex, obesity and dyslipidemia status and their 
characteristics were described using median and interquartile range, if continuous, and percentages, if categor-
ical (Table 1). Comparison of serum cholesterol and triglycerides were performed using Mann-Whitney U-test. 
Circulating levels of Cer and SM were transformed as logarithm and were compared by sex, weight group and 
dyslipidemia status using a generalized linear model (GLM) adjusted for BMI and age. Retro transformed least 
square means from the GLM models were reported along with their standard errors and comparisons were per-
formed using the Tukey adjustment to control for inequalities of groups sizes60. For LC-MS analysis, sera were 
randomly sub-pooled into 4 matched groups of men and women considering biometric parameter and HPTLC 
quantitative profiles. The pooling was adopted as a method to reduce the variance among biological groups 
increasing the power to detect changes when few samples are available and the variance is high61,62. All statistical 
analyses were performed using the SAS software version 9.4. Statistical tests were two tailed and type-I error rate 
was set at 5% (α = 0.05).
Data availability
The data generated during and/or analysed during the current study are included in this published article (and 
its Supplementary Information files). When needed, further information are available from the corresponding 
author on reasonable request.
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